|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses | |||||
| Research and development | |||||
| Cost to acquire IPR&D asset | |||||
| General and administrative | |||||
| Change in estimate for legal contingency | |||||
| Change in estimate for legal contingencies | |||||
| Income from insurance recovery | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other (income) expense | |||||
| Change in fair value of derivative liability | |||||
| Gain on forgiveness of PPP loan | |||||
| Interest expense | |||||
| Interest income | |||||
| Finance charge | |||||
| Wind-down costs | |||||
| Gain from asset sale | |||||
| Debt conversion inducement expense | |||||
| Other expense | |||||
| Total other (income) expense, net | |||||
| Loss before income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Loss per common share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average shares of common stock outstanding used to compute loss per share: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...
